The activation of insulin/IGF-dependent pathways has been established as a key step that contributes to several mechanisms of CRC resistance to conventional and targeted therapeutic drugs [26], which makes it a promising target for CRC multi-target therapy. This evidence concerns the gene IGF1 and colorectal carcinoma.